CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010
Cash flows from operating activities:
Net loss	$ (7,616,791)	$ (8,693,096)
Adjustments to reconcile net loss to net cash flows from operating activities, net of effects of acquisition:
Depreciation	330,851	337,594
Amortization of intangible assets	1,001,931	500,949
Amortization of debt discount and deferred financing costs	246,807	499,610
Employee share-based compensation expense	1,032,261	731,216
Other share-based compensation expense	285,154	105,062
Increase (decrease) in cash resulting from changes in:
Accounts receivable	(818,102)	(230,731)
Inventory	(150,479)	(86,901)
Prepaid expenses and other current assets	(161,010)	(2,392)
Other assets	(48,174)	57,957
Accounts payable and accrued expenses	833,013	609,276
Accrued interest	65,281	0
Other liabilities	(9,825)	0
Net cash flows from operating activities	(5,009,083)	(6,171,456)
Cash flows from investing activities:
Purchases of equipment	(417,900)	(149,183)
Cash paid for acquisition, net of cash aquired of $33,583	(466,417)	0
Net cash flows from investing activities	(884,317)	(149,183)
Cash flows from financing activities:
Proceeds from Note Payable with related party	1,300,000	0
Repayment of Line of Credit	(99,000)	0
Repayment of Notes Payable	(50,671)	0
Proceeds from sale of common stock and warrants and common stock with registration rights, net	3,743,588	785,000
Proceeds from exercise of stock options	295,753	102,626
Proceeds from exercise of warrants	0	3,207,969
Net cash flows from financing activities	5,189,670	4,095,595
Net change in cash	(703,730)	(2,225,044)
Cash, beginning of period	1,340,922	2,653,537
Cash, end of period	637,192	428,493
Supplemental disclosure of cash flow information:
Cash paid for interest	4,842	0
Cash paid for income taxes	0	0
Supplemental disclosure of non-cash financing activity:
Outstanding convertible debt and accrued interest	406,664	7,135,114
Stock valued in conjunction with its acquisition of Surgical Biologics, LLC	7,087,500
Shares issued in conjunction with its acquisition of Surgical Biologics, LLC (in shares)	5,250,000
Beneficial conversion feature value related to the convertible debt issued with regard to its acquisition of Surgical Biologics, LLC	437,500
Beneficial conversion feature related to convertible line of credit	80,000
Amortization of debt discount and deferred financing costs related to the conversion of convertible debt		$ 599,001